The single-arm trial met its primary end point of complete response (CR) at any time, exceeding historic and contemporary ...

New KRAS-targeting drug for metastatic pancreatic cancer nearly doubles second-line survival; expert explains impact, side effects, next trials.

Chromosome 13q linkage promotes RB1 hemizygosity during BRCA2 LOH, lowering the ‘two-hit’ barrier and predisposing to ...

MCED screening and broader genetic testing push community oncology toward prevention—learn how practices adapt workflows, ...

Objective response rate was 35% (3 CR, 3 PR), with most patients demonstrating primary progression despite meeting ...

Betts, MD, discusses how PTCy and tacrolimus protocols, as well as using younger donors, contributes to higher survival rates ...

AI-built social posts aim to raise young women’s awareness that alcohol increases breast cancer risk, while a trial tracks ...

Joseph Mikhael, MD, MEd, discusses the potential and limitations of at-home cancer care using on-body injection technology.

This is part 4 of an interview. Watch part 1, part 2, and part 3.

As administrators, physicians, and researchers at cancer centers, we are well aware of the significant impact that the COVID-19 pandemic is having on cancer care worldwide. We are dealing with what I ...

Betts, MD, discusses how discharging patients as early as day 5 after stem cell transplant has proved feasible and improves quality of life. Brian C. Betts, MD, Vice Chair of Strategic Initiatives for ...

Dr. Monty Pal discusses how the increasing use of adjuvant immunotherapy has introduced new considerations for the management ...